BioWorld Asia

Nov. 1, 2006

CAT's Humira Royalty Sold By AstraZeneca For $700M

LONDON - AstraZeneca plc, the new owner of Cambridge Antibody Technology Group (CAT) Ltd., sold the royalty rights to the antibody company's one marketed product, Humira, for $700 million. (BioWorld International) Read More

Hold On Paion's Desmoteplase Lifted; Phase III Back On Track

Schizophrenia Gene Study Reveals Influence On Brain

Ethics Questions Delay Europe's Decision On Advanced Therapies

Cytheris' €24M Series B Round Should Fuel Company Into 2009

No Abstract Read More

Innate Planning For IPO, Seeking €25M To €36M

No Abstract Read More

LibraGen Enters Research Deal With Sanofi-Aventis

Renovo Reports Positive Data In Third Juvista Phase II Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 6, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...